the impact of pretreatment prognostic factors and early changes in serum biomarkers on survivals in patients with mHNPC.
METHODS: We retrospectively reviewed the medical records of 629 patients with newly diagnosed mHNPC who were initially treated with androgen deprivation therapy (ADT) from 2008 to 2016. We investigated 330 patients whose laboratory data were available at baseline and at 2-4 months. The final multivariable Cox proportional hazards regression model was developed using the lowest Akaike Information Criterion and highest score, confirming the proportional hazard assumption.
RESULTS: The median OS was 6.47 years (median follow-up, 2.53 years). The final Cox models demonstrated that the higher half value of prostate-specific antigen (PSA) >3.1 ng/mL and the lower half value of hemoglobin (HGB) 12g/dL in 2-4 months after ADT were independently associated with worse cancer specific survival (CSS) and overall survival (OS) along with the extent of osseous disease with !2, and higher half value of lactate dehydrogenase >220 U/L at baseline. Based on the presence of zero, one, or two prognostic factors of serum PSA and HGB levels at 2-4 months, the risk group analysis showed that median OS estimates for these groups were 2.76, 5.65, and 7.87 years, respectively.
CONCLUSIONS: Risk classification based on early changes in serum biomarker levels may be a promising for identifying patients with poor survival. Not only pretreatment risk factors but also early changes in serum biomarker levels may be useful for predicting poor outcomes in patients with mHNPC.
Source of Funding: None

MP28-10 SYSTEMIC METABOLIC RESPONSES OF PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY (ADT) WITH AND WITHOUT LOW CARB DIET
Jen-Tsan Chi*, Pao-Hwa Lin, Durham, NC; Emily Chen; Vladimir Tolstikov, Framingham, MA; Taofik Oyekunle, Durham, NC; Fei Gao, Rangaprasad Sarangarajan, Niven Narain, Michael Kiebish, Framingham, MA; Stephen Freedland, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) is linked with metabolic disturbances such as impaired glucose tolerance, insulin resistance, weight gain, and bone loss, putting men at increased risk of diabetes and cardiovascular death. However, the metabolic pathways altered by ADT and how this occurs is unknown. In a prospective 6-month randomized trial, we showed many of these metabolic disturbances are prevented by a low carbohydrate diet (LCD) intervention with advice to walk more vs. control (asked to make no lifestyle changes). We used banked serum from this trial to assess the metabolomic changes due to ADT alone or ADT plus LCD in prostate cancer (PC) patients.
METHODS: Sera collected at baseline, 3-, and 6-month was used for metabolomics and lipidomics analyses. The relevant metabolic changes associated with each treatment and ADT-affected androgen reduction were identified by one-way ANOVA, MetaboAnalyst analysis, and Pearson correlation.
RESULTS: 42 patients were randomized (N[20 LCD, N[22 control), 40 completed baseline (N[19 LCD, N[21 control ) and 34 completed 6-month visit but only 29 had blood collected (LCD:11/14; control: 18/20). First, as expected, ADT alone reduced steroid synthesis as reflected by lower androgen sulfate and other steroid hormones. The degree of androgen reduction was negatively correlated with serum glucose (r[-0.66), supporting the diabetogenic role of ADT. Second, a consistent reduction in 3-hydroxybutyric acid was observed, indicating reduced ketogenesis. Third, ADT was associated with a corresponding reduction in Indole-3-carboxaldehyde, a microbiota-derived metabolite from dietary tryptophan. Indole-3-carboxaldehyde is an agonist for the aryl hydrocarbon receptor in intestinal immune cells to stimulate the production of IL22 which regulates mucosal reactivity and inflammation. Lastly, ADT alone also reduced fatty acid metabolism, acyl-carnitines, increased SAH, SAM, uremic toxins (p-cresol, p-cresol sulfate) and oAcetylserine. Combining ADT with a LCD reversed many of the ADTassociated metabolic changes, including reduced ketogenesis and Indole-3-carboxaldehyde, suggesting its potential to mitigate ADT-linked metabolic dysregulation.
CONCLUSIONS: Metabolomic analysis identified important mechanistic insights of metabolic dysregulation of ADT including ketogenesis and microbial production of indoles which is related to immune pathways. Future research is needed to confirm the findings and examine further the underlying mechanisms and functional impact of ADT and the reversal of a LCD on metabolic homeostasis to prevent ADT-linked comorbidities.
Source of Funding: Atkins Foundation, AUA, NIH, and Berg.
MP28-11 ELEVATED SERUM GAMMA-GLUTAMYLTRANSFERASE IS AN ADVERSE PROGNOSTIC FACTOR IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE
Kosuke Takemura*; Masaya Ito; Yasukazu Nakanishi, Madoka Kataoka, Kazumasa Sakamoto, Hiroaki Suzuki, Noriyuki Iida, Ken-ichi Tobisu, Fumitaka Koga, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Gamma-Glutamyltransferase (GGT) is a well-established serum biomarker for hepatobiliary dysfunction. GGT is also known as a membrane-bound enzyme implicated in neutralizing reactive oxygen compounds and free radicals. The elevation of serum GGT has recently been reported to be linked to decreased survival in various malignancies. However, there is no report on prognostic roles of GGT in castration-resistant prostate cancer (CRPC). The aim of this study is to evaluate the prognostic significance of serum GGT in CRPC patients treated with enzalutamide.
METHODS: A total of 50 consecutive CRPC patients treated with enzalutamide at a single cancer center between 2014 and 2018 were retrospectively evaluated. Overall survival (OS) was defined as the time from the initiation of enzalutamide to either death or the last follow-up. Other variables collected included age, performance status, Gleason score, pretreatment, opioid usage, lymph node/visceral metastases, hemoglobin (Hgb), albumin, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), C-reactive protein, and prostatespecific antigen (PSA) at the initiation of enzalutamide. The difference in the Kaplan-Meier curves was evaluated by log-rank test. Associations of variables with OS were analyzed by Cox proportional hazard model. The accuracy of prognostic models was assessed by Harrell's c-index.
